ARCT - Arcturus Therapeutics Holdings Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Show:
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
2022-12-31
2021-12-31
2020-12-31
2019-12-31
Total Revenue
205,755
205,755
12,359
9,539
20,789
Operating Expenses
Research Development
147,751
147,751
173,760
57,846
33,640
Selling General and Administrative
46,071
46,071
41,451
23,217
12,662
Total Operating Expenses
193,578
193,578
215,211
81,063
46,302
Operating Income or Loss
12,177
12,177
-202,852
-71,524
-25,513
Interest Expense
3,001
420
2,674
361
446
Total Other Income/Expenses Net
-1,113
-1,113
1,099
-263
-32
Income Before Tax
10,644
10,644
-203,674
-72,148
-25,991
Income Tax Expense
1,295
1,295
-
-
-
Income from Continuing Operations
9,349
9,349
-203,674
-72,148
-25,991
Net Income
9,349
9,349
-203,674
-72,148
-25,991
Net Income available to common shareholders
9,349
9,349
-203,674
-72,148
-25,991
Basic EPS
-
0.35
-7.74
-3.55
-2.15
Diluted EPS
-
0.35
-7.74
-3.55
-2.15
Basic Average Shares
-
26,445
26,317
20,305
12,069
Diluted Average Shares
-
27,093
26,317
20,305
12,069
EBITDA
-
11,064
-199,807
-71,787
-25,545